Troponin I phosphorylation in human myocardium in health and disease

P. J.M. Wijnker, A. M. Murphy, G. J.M. Stienen, J. van der Velden

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Cardiac troponin I (cTnI) is well known as a biomarker for the diagnosis of myocardial damage. However, because of its central role in the regulation of contraction and relaxation in heart muscle, cTnI may also be a potential target for the treatment of heart failure. Studies in rodent models of cardiac disease and human heart samples showed altered phosphorylation at various sites on cTnI (i.e. site-specific phosphorylation). This is caused by altered expression and/or activity of kinases and phosphatases during heart failure development. It is not known whether these (transient) alterations in cTnI phosphorylation are beneficial or detrimental. Knowledge of the effects of site-specific cTnI phosphorylation on cardiomyocyte contractility is therefore of utmost importance for the development of new therapeutic strategies in patients with heart failure. In this review we focus on the role of cTnI phosphorylation in the healthy heart upon activation of the beta-adrenergic receptor pathway (as occurs during increased stress and exercise) and as a modulator of the Frank-Starling mechanism. Moreover, we provide an overview of recent studies which aimed to reveal the functional consequences of changes in cTnI phosphorylation in cardiac disease.

Original languageEnglish (US)
Pages (from-to)463-469
Number of pages7
JournalNetherlands Heart Journal
Issue number10
StatePublished - Oct 1 2014


  • Cardiac troponin I
  • Heart failure
  • Myofilament function
  • Phosphorylation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Troponin I phosphorylation in human myocardium in health and disease'. Together they form a unique fingerprint.

Cite this